Literature DB >> 22371939

Framingham risk-based survival of non-small-cell lung cancer.

Michael Poullis1, James McShane, Matthew Shaw, Richard Page, Michael Shackcloth, Neeraj Mediratta.   

Abstract

This study was undertaken to determine whether the Framingham cardiovascular risk prediction model can identify patients who will have reduced 5-year survival after resection for primary lung cancer. The Framingham risk model for predicting cardiovascular death rates in a 5-year period was calculated for 1,981 patients undergoing resection for non-small-cell lung cancer. Receiver operator curve analysis was performed to determine a cutoff with regard to Framingham risk, and this was utilized to construct Kaplan-Meier survival curves for stages I, II, and III. Cox regression analysis was used to determine factors significantly affecting long-term survival. The Framingham risk model predicted that 0.015% to 26.7 % (mean, 5.2%) of our patients would die over a 5-year period. Univariate analysis revealed the Framingham score as being significant for stages I and II, but not III. Cox regression analysis demonstrated age, body mass index, pneumonectomy, stage I, stage III, stage IV, and Framingham score were all significant determinants of 5-year survival. Framingham-based cardiovascular risk prediction in patients undergoing resection for non-small-cell lung cancer stages I and II defined a group with significantly worse 5-year survival.

Entities:  

Mesh:

Year:  2012        PMID: 22371939     DOI: 10.1177/0218492311432801

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  2 in total

1.  The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.

Authors:  W Law; C Johnson; M Rushton; S Dent
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

2.  Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis.

Authors:  J Wang; H Xu; S Zhou; D Wang; L Zhu; J Hou; J Tang; J Zhao; S Zhong
Journal:  Eur J Clin Nutr       Date:  2017-05-17       Impact factor: 4.016

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.